INTRODUCTION
Common variable immunodefi ciency (CVID) is the most frequent symptomatic primary immunodefi ciency, which is characterized by failure of B-cell diff erentiation and decreased production of immunoglobulins. CVID is a combination of humoral and cell-mediated defi ciency; this could be the reason for the multi-system involvement in the CVID patients, and the ineffectiveness of the intravenous immunoglobulin (IVIG) as standard therapy to prevent complications of the CVID patients. [1] The most common symptoms are severe, recurrent and sometimes chronic bacterial infections, mostly of the respiratory and gastrointestinal tracts and an increased incidence of lymphoproliferative processes, which may predispose to neoplasia. [2] The onset of CVID is at >2 years of age. [3] There is no precise information on the
The diff erentiation and survival of Th17 cells share critical clues with the B-cell diff erentiation and the follicular T helper (T FH ) subset, which was recently shown to be enriched in Th17 cells to help B-cell diff erentiation. [12] B-cell diff erentiation in the germinal centers (GCs) is also required or may contribute to the induction and/or survival of Th17 cells. [13] It is reported that about 25-48% of the CVID patients are influenced by diverse autoimmune diseases (more thrombocytopenic purpura and hemolytic anemia), which are usually the fi rst manifestation of this immune defi ciency. [3, 14] A subset of lymphocytes which is called the innate lymphoid cells (ILCs), represents an emerging family of cell types which seems to have crucial roles in the tissue remodeling and in innate immunity to the pathogenic and nonpathogenic microorganisms. [15] These cells are determined by a lymphoid morphology and a lack of receptors dependent on the RAG recombinase, encoded by the recombination activating genes. [16] Among these ILCs, one of them overlap with the Th17 cells and produce IL-17 and IL-22.
[17] These ILCs do not express the lymphoid lineage markers (Lin − ), but are RORγt (RORC2), Thy-1 (CD90) and the IL-7 receptor-α (CD127) positives. [17] There is some evidence to suggest that also IL-9 is produced by the Th17 cell. [18] New reports have demonstrated that IL-9 increased in the autoimmune diseases such as, systemic lupus erythematosus (SLE), systemic sclerosis, and rheumatoid arthritis (RA). [19] [20] [21] In general, these data implicate IL-9 as a cytokine which contribute to the autoimmune disease. Consequently, the current study aimed to evaluate the Th17 cell specifi c genes expression (as the determiners of Th17 cells) and IL-17-producing ILCs along with the measurement of messenger ribonucleic acid (mRNA) level of IL-9 in the CVID patients.
MATERIALS AND METHODS

Subjects
Ten CVID cases and 10 healthy controls (fi ve males and fi ve females per group) were enrolled in the study. The characteristics of CVID patients are summarized in Table 1 .
The CVID patients were diagnosed according to the European Society for the Immunodefi ciency Criteria namely: decreased serum IgG as well as IgM and/or IgA levels at least two standard deviations below the normal mean for age, impaired antibody response to vaccines, absent/low isohemagglutinins, and exclusion of defined causes of hypogammaglobulinemia. [22] Nobody was receiving the IVIG before sampling. Healthy controls were selected from age matched volunteers without any sign, symptom and history of immunodefi ciency and/or autoimmunity.
All subjects had signed informed consent for the blood sampling and processing. The ethical aspects of this study were approved by the Infectious Diseases and Tropical Medicine Research Center and Ethical Commi ee of Isfahan University of Medical Sciences, Isfahan, Iran (Project number : 188128).
IL-17, RORC2, IL-23R, and IL-9 were detected in the peripheral blood of patients with CVID by the real-time polymerase chain reaction (PCR). We also evaluated the frequency of the ILCs producing IL-17 in the peripheral blood of the CVID patients, using the flow cytometry method with a standard panel of monoclonal antibodies following the manufacturer's instructions.
Real-time quantitative reverse transcriptase-PCR
Total RNA was extracted using the Thermo Scientifi c Gene JET RNA Purifi cation Kit (Thermo, Fermentas, USA). Then, 1 μg of total RNA was converted into the complementary deoxyribonucleic acid (cDNA) using Aid First Strand cDNA Synthesis Kit (Thermo, Fermentas, USA) as instructed by the manufacturer. The resulting transcripts were then quantifi ed by the real-time quantitative PCR on a StepOne plus™ real-time DNA amplifi cation system (Applied Biosystems, USA) using SYBR ® Premix Ex Taq™ II kit (Takara, Japan) according to the manufacturer's instructions. Pre-designed primers (QuantiTact Primer Assay; Qiagen, Netherlands) specifi c for amplifi cation of IL-17, RORC2, IL-23R, and IL-9 were applied. For each sample, transcript quantity was normalized to the amount of beta-actin expression. Amplifi cation was carried out in a total volume of 20 μl for 40 cycles of 30 s at 95°C and 30 s at 60°C.
Cell staining and fl ow cytometric analysis
Whole blood samples with the ethylenediaminetetraacetic acid were collected and lysed using a red blood cell lysis solution (CMG, Iran) according to the manufacturer's instructions. Staining for fl ow cytometry was performed using the fluorescein isothiocyanate (FITC)-conjugated anti-CD3, anti-CD19 (eBiosciences, USA), and anti-CD56 antibody (NCAM) (Santacruz Biotech, USA), all for lineage exclusion; peridinin chlorophyll protein (PerCp)-conjugated anti-human CD127 (IL-7Rα) antibody (R&D Systems, USA) and phycoerythrin (PE)-conjugated anti-human CD90 (Thy-1) antibody (eBiosciences, USA) for detecting ILCs. [17] A minimum of 100,000 lymphocytes were acquired per sample. Prepared samples were acquired on a FACScan and data were analyzed with the CellQuest-Pro so ware (BD Biosciences, San Jose, CA, USA). In order to further investigate the relationship between the IL-17 producing cells and the CVID patients, we counted IL-17 producing ILCs, represented by Lin
+ phenotype, in the peripheral blood of the cases and controls using the fl ow cytometry method. At the fi rst, in order to exclude the T-cells, B-cells, and natural killer (NK) cells which express CD3, CD19 and CD56, respectively, we analyzed the cells for the absence of these markers (e.g., Lin 
Statistical analysis
The results were analyzed statistically with the independent sample t-test using SPSS 16.0 software (Chicago, USA). Results are expressed as mean ± standard error of mean, and P < 0.05 were considered to be signifi cant. Table 1 summarizes the clinical characteristics of the CVID patients and control subjects. Three out of 10 CVID patients were suff ering from the autoimmune diseases. Our results displayed that relative expression of IL-17 (1.22 ± 0.22 vs. 2.21 ± 0.95) and RORC2 (1.0 ± 0.65 vs. 3.01 ± 2.06) genes in the CVID patients were signifi cantly less than the controls (P = 0.049 and P = 0.046, respectively). However, this diff erence for the IL-23R mRNA level was insignifi cant (P = 0.99 ± 0.29 vs. 1.23 ± 0.44, P = 0.252). Reversely, we observed that gene expression level of the IL-9 in the CVID patients was increased signifi cantly compared with the controls (9.67 ± 0.27 vs. 1.54 ± 0.88, P = 0.001) [ Figure 2 ]. Table 2 shows the detailed information of the cytokines mRNA levels in the patients and normal groups. Our results showed that the number of Lin − /CD127 + /CD90 + ILCs were signifi cantly lower in the peripheral blood of the CVID patients compared with the healthy individuals (0.0% vs. 0.036% ±0.02, respectively, P = 0.04) [ Figure 1 ].
RESULTS
DISCUSSION
The present study is aimed to measure the Th17 cell specifi c gene expression, to measure the mRNA level of IL-9, and to count the ILCs in the peripheral blood of the CVID patients. The frequencies of IL-17 producing cells in the CVID patients was markedly decreased compared with the healthy individuals. These cells are known to be involved in inducing infl ammation and autoimmunity. [23] On the other hand, IL-17 alone promotes the human B-cell survival and synergizes with the B-cell activating factor to induce the B-cell proliferation and diff erentiation into the antibody secreting plasma cells. [24] Accordingly, it is shown that the Th17 cells act as B-cell helpers. [25] Our results showed that the transcript levels of IL-17 in the CVID patients were decreased signifi cantly. Barbosa et al. (2011) have shown decreased frequency of IL-17 producing CD4 + T in CVID patients compared with the healthy individuals. [13] IL-17 is also produced by CXCR5 + CD4 + (T FH ) cells and according to a study, the circulating CXCR5 + CD4 + T-cell (T FH ) population were signifi cantly diminished in the CVID patients compared with the healthy subjects. [26, 27] Therefore, this decrease of IL-17 in the CVID patients may be a ributable to their diminished T FH population. Our fi ndings are consistent with the results of these studies.
As RORC2 is the key transcription factor for Th17 phenotype it seems that this factor, along with IL-17, can be a specifi c marker, which helps to be er characterizing Th17 cells. [7, 9] Our fi ndings showed a signifi cant decrease in the transcript level of RORC2 in the CVID patients. This is consistent with the diminished frequency of Th17 cells in the CVID patients reported by Barbosa et al. [13] This fi nding also agreed with the corresponding diseases such as, ICOS-defi cient and hyper-IgE patients. [28, 29] We also showed that the transcript levels of IL-23R, another Th17 characteristic gene decreased slightly or remained unchanged in patients with CVID. This slight decrease may be due to the expression of IL-23R on other cells such as NK cells, dendritic cells and memory T-cells. [30] We did not fi nd any report in this context in order to compare with our fi ndings. However, this fi nding is consistent with the diminished Th17 cell count in the Barbosa's report and reduced RORC2 and IL-17 mRNA levels as other Th17 characteristic genes in the present study.
On an average 70-80% of the CVID patients have recurrent sinopulmonary infections, autoimmunity and infl ammatory complications. The most common autoimmune conditions are immune thrombocytopenic purpura and hemolytic anemia, but other autoimmune complications arise including RA, pernicious anemia, primary biliary cirrhosis, thyroiditis, sicca syndrome, SLE, and IBD. [14, 31] We next assessed whether these infl ammatory and autoimmune manifestations could be related to an expansion of the Th17 cells, as reported in the other autoimmune se ings. [32] There was not any increase in the Th17 cell specifi c genes expression in the CVID patients with autoimmunity, even when the CVID patients were classifi ed according to the type of the autoimmune manifestation.
Interestingly, we showed that IL-9 mRNA level in the peripheral blood samples of the CVID patients was signifi cantly more than the controls. As shown in Table 2 , this increase was too high in two patients with the autoimmune thrombocytopenia (patient 5) and chronic arthritis (patient 7). In addition, in one patient with the autoimmune hepatitis (patient 2), IL-9 gene expression IL-17, RORC2, IL-23R and IL-9 in the control subjects and was increased signifi cantly. IL-17 was diminished strongly in these three patients as well. One study has shown no increase in the level of IL-17 in the CVID patients associated with the Crohn's disease, as compared with the healthy individuals. [2] This fi nding is consistent with our results.
According to several studies about the relation of IL-9 and its increase in some of the autoimmune diseases such as SLE, systemic sclerosis, and RA. [19] [20] [21] Our fi ndings suggest that the increase of IL-9 mRNA level may has a role in the pathogenesis of autoimmunity in our CVID patients. However, its exact role and mechanisms need to be confi rmed.
Moreover, according to the role of IL-9 in Th17 cells expansion, one can suppose that decreased number of the Th17 cells in the CVID patients may lead to an increase in the IL-9 level as a compensatory aff ect. On the other hand, in some studies it is demonstrated that IL-9 may exerts anti-infl ammatory eff ects in several cells or experimental autoimmune models, presumably through the indirect inhibition of the production of proinfl ammatory cytokines. [21] Therefore, increased IL-9 level in the CVID patients might have a casual relation with the IL-17 reduction.
The level of IL-9 transcript was signifi cantly high in one patient without any apparent autoimmunity (patient 4). However, she had two children with the lymphoma disease. It is shown that IL-9 may relate to the Hodgkin lymphoma. [33] Furthermore, according to its growth/ proliferative and anti-apoptotic activities on the diff erent transformed cells, a potential role for this cytokine might be tumorigenesis. [34] In addition, over-expression of IL-9 induces thymic lymphomas in mice, and IL-9 production is associated with the Hodgkin disease and human T-lymphotropic virus type-1 transformed T-cells in human. [35] Nevertheless, this patient by herself is not aff ected by lymphoma.
The mRNA level of IL-9 was also high in three other patients; patient 6 with respiratory and ocular allergy, patients 8 and 10 with respiratory allergy.
The eff ects of IL-9 have been shown in the development and maintenance of allergic inflammation and airway remodeling. The number of IL-9 mRNA-positive cells in the airway of patients with atopic asthma and allergic rhinitis has shown to be elevated. [36, 37] This is consistent with our fi ndings.
In order to further investigate the IL-17 producing cells, we evaluated the IL-17-producing ILCs population in patients with CVID. These cells are of lymphoid origin [16] and express IL-7 receptor α-chain (CD127) and Thy-1 (CD90) and are lineage negative. [17] There is a paucity of information regarding the ILCs count in diff erent diseases, and this was the fi rst study, which evaluated the ILCs count in the peripheral blood of patients with CVID so far. We showed that the ILCs count in the CVID patients was signifi cantly lower than the controls (0% vs. 0.036% respectively). Average percentage of these cells was 0.036% in the healthy individuals and this is consistent with the study of Mjösberg, who reported this frequency as 0.01-0.03% in the normal population.
[16]
CONCLUSIONS
The results presented in this study show that the Th17 cell specifi c genes expression (as the determiner Th17 cells) and ILCs (another lymphoid source of IL-17) are decreased in patients with CVID and this could be an explanation for the defect of their humoral immune response. In addition, elevation of the IL-9 gene expression may shed a new light into the way toward the understanding of the mechanism of autoimmunity in the CVID patients.
